Introduction
Osteoporosis continues to be an attractive therapy area for large pharmaceutical companies due to its high prevalence rate and unmet need. Globally, sales for osteoporosis drugs grew 7.0% year-on-year from 2004 to $9.6 billion in 2008 driven by strong performance of the bisphosphonate class.
Reasons to Purchase
*Understand current and future osteoporosis drug market dynamics
*Gain insight into the unmet needs of current osteoporosis treatment and to what extent pipeline drugs will address these issues
*Evaluate the sales forecasts of marketed, generic, and key pipeline drugs to 2018 in the US, Japan, France, Germany, Italy, Spain, and the UK
Other selected research from the 'Markets' category:
Clinical Trials: World Market 2009-2024
The market for clinical trials has been expanding rapidly in recent years, with impressive revenue growth and important trends. From the perspectives of various pharma stakeholders, the expanding clinical research market represents opportunities for revenue growth and cost savings. Learn More
The Biotechnology Market Outlook: Growth opportunities and effective strategies for licensing and collaborations
In 1982 the US Food and Drug Administration (FDA) approved the first biotech drug, human insulin, which was produced in genetically modified bacteria; since Genentech went public back in 1980 the biotech sector has been marked by periodic boom-and-bust cycles in the stock market. Learn More